These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27168431)

  • 21. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 23. Improving the PPI sample for prescription pharmaceuticals.
    Kelly GG
    Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
    [No Abstract]   [Full Text] [Related]  

  • 24. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Competition and prices in the Mexican pharmaceutical market].
    Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
    Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability.
    Wang YR
    Appl Health Econ Health Policy; 2005; 4(3):147-51. PubMed ID: 16309331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 30. The new drug war.
    Sherrid P
    US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceutical pricing conundrum: time to get rid of it?
    Garattini L; Padula A
    Eur J Health Econ; 2018 Nov; 19(8):1035-1038. PubMed ID: 30030646
    [No Abstract]   [Full Text] [Related]  

  • 32. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 33. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 34. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 35. The scandal of generic drug pricing: drug regulation policies need review.
    Meeran K; Choudhury SM; Wass J
    BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
    [No Abstract]   [Full Text] [Related]  

  • 36. [Parallel import of drugs for better and for worse].
    Krabbe U
    Ugeskr Laeger; 2004 Feb; 166(7):611. PubMed ID: 15005051
    [No Abstract]   [Full Text] [Related]  

  • 37. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 38. [Parallel import of drugs].
    Rygnestad T; Fredriksen G; Spigset O
    Tidsskr Nor Laegeforen; 1999 Apr; 119(11):1573. PubMed ID: 10385794
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.